2cureX Beheer

Beheer criteriumcontroles 2/4

De CEO 2cureX is Ole Thastrup, benoemd in Jan2006, heeft een ambtstermijn van 18.83 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 300.00K, bestaande uit 50% salaris en 50% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 23.8% van de aandelen van het bedrijf, ter waarde SEK 2.00M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 2 jaar.

Belangrijke informatie

Ole Thastrup

Algemeen directeur

SEK 300.0k

Totale compensatie

Percentage CEO-salaris	50.0%
Dienstverband CEO	18.8yrs
Eigendom CEO	23.8%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ole Thastrup's beloning veranderd ten opzichte van 2cureX's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-SEK 26m
Mar 31 2024	n/a	n/a	-SEK 30m
Dec 31 2023	SEK 300k	SEK 150k	-SEK 33m
Sep 30 2023	n/a	n/a	-SEK 33m
Jun 30 2023	n/a	n/a	-SEK 31m
Mar 31 2023	n/a	n/a	-SEK 29m
Dec 31 2022	SEK 150k	n/a	-SEK 30m
Sep 30 2022	n/a	n/a	-SEK 29m
Jun 30 2022	n/a	n/a	-SEK 26m
Mar 31 2022	n/a	n/a	-SEK 25m
Dec 31 2021	SEK 150k	n/a	-SEK 19m
Sep 30 2021	n/a	n/a	-SEK 15m
Jun 30 2021	n/a	n/a	-SEK 10m
Mar 31 2021	n/a	n/a	-SEK 8m
Dec 31 2020	SEK 2m	SEK 2m	-SEK 7m
Sep 30 2020	n/a	n/a	-SEK 7m
Jun 30 2020	n/a	n/a	-SEK 8m
Mar 31 2020	n/a	n/a	-SEK 8m
Dec 31 2019	SEK 2m	SEK 2m	-SEK 8m
Sep 30 2019	n/a	n/a	-SEK 6m
Jun 30 2019	n/a	n/a	-SEK 6m
Mar 31 2019	n/a	n/a	-SEK 6m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 7m

Compensatie versus markt: De totale vergoeding ($USD 27.17K ) Ole } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 236.30K ).

Compensatie versus inkomsten: De vergoeding van Ole is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ole Thastrup (71 yo)

18.8yrs

Tenure

SEK 300,000

Compensatie

Mr. Ole Thastrup is CEO of 2cureX AB (publ) since June 2024 and serves as it's Vice Chairman of the Board since January 01, 2024 and served as the Chief Scientific Officer since January 2021 until January...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ole Thastrup	Co-Founder	18.8yrs	SEK 300.00k	23.8% SEK 2.0m
Grith Hagel	Co-Founder	no data	geen gegevens	3.87% SEK 325.9k
Kenneth Johansen	Chief Financial Officer	3.8yrs	geen gegevens	0.023% SEK 1.9k
Jacob Thastrup	Chief Technology Officer	less than a year	geen gegevens	0.062% SEK 5.2k
Manuel Fernandez	Director Quality & Regulatory Affairs	no data	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2CUREX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ole Thastrup	Co-Founder	18.8yrs	SEK 300.00k	23.8% SEK 2.0m
Grith Hagel	Co-Founder	less than a year	geen gegevens	3.87% SEK 325.9k
John Marshall	Member of Clinical Advisory Board	3.3yrs	geen gegevens	geen gegevens
Tonni Bülow-Nielsen	Chairman of the Board	less than a year	geen gegevens	geen gegevens
Jesus Garcia-Foncillas	Member of Clinical Advisory Board	3.3yrs	geen gegevens	geen gegevens
Andrew Beggs	Member of Clinical Advisory Board	3yrs	geen gegevens	geen gegevens
Nathaniel Hutley	Director	less than a year	geen gegevens	geen gegevens
Dan Honeywell	Director	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 2CUREX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw bestuur.

2cureX Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

2cureX AB (publ) Approves the Election of New Board Members

2cureX AB (publ) Announces CEO Changes

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

2cureX AB (publ), Annual General Meeting, May 23, 2024

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

Recent updates

2cureX AB (publ) Approves the Election of New Board Members

First half 2024 earnings released: kr0.54 loss per share (vs kr0.89 loss in 1H 2023)

2cureX AB (publ) to Report Fiscal Year 2024 Final Results on Apr 24, 2025

2cureX AB (publ) Announces CEO Changes

2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022)

2cureX AB (publ), Annual General Meeting, May 23, 2024

2cureX AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial

Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022)

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

New minor risk - Share price stability

2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation

New major risk - Financial position

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022)

Chief Executive Officer recently bought kr136k worth of stock

Chief Executive Officer recently bought kr136k worth of stock

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

2cureX AB (publ) Appoints Michel Klimkeit to Board of Director

2cureX AB (publ) to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021)

High number of new and inexperienced directors

2cureX AB (publ), Annual General Meeting, May 25, 2023

2cureX Announces Board Change

Chief Executive Officer recently bought kr84k worth of stock

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

2cureX AB (publ) Presents Inditreat® Clinical Results At the Society for Functional Precision Medicine

High number of new and inexperienced directors

Manuel Fernández Joins 2cureX as Director of Quality Assurance and Regulatory Affairs

2cureX AB (publ) Announces Management Changes

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

2cureX Launches IndiTreat mCRC Start Test to Guide First Line Treatment

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

2cureX Announces New Development of the IndiTreat Technology Allows Prediction of Response to Anti-Angiogenic Drugs in Colorectal Cancer

High number of new and inexperienced directors

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

2Curex AB (Publ) Clinical Partner, University Hospital Vejle, Presents Positive Results of Thnditreat®-Guided Clinicaical Trial in Third Line Metastatic Colorectal Cancer At the Asco 2021 Annual Meeting

Co-Founder exercised options to buy kr7.6m worth of stock.

2cureX AB (publ) Announces Clinical Trial of Inditreat®-Guided Treatment of Metastatic Colorectal Cancer

2cureX AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return

2cureX AB's IndiTreat® Selected to Prestigious Multinational Ovarian Cancer Project

New 90-day high: kr22.60

Chief Financial Officer has left the company

2cureX Appoints Kenneth Graabek Johansen as New CFO, Effective 1 February 2021

2cureX Announces Last Patient Treated in the World's First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day high: kr17.65

2cureX Announces Management Changes

2cureX AB (publ), Annual General Meeting, May 27, 2021

How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?

New 90-day low: kr16.25

2cureX Announces Last Patient Successfully Enrolled in the Worlds First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day low: kr17.30

2cureX launches world's first CE-marked microtumor test service

New 90-day high - kr22.50

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam